FENGYUAN PHARMACEUTICAL(SZ:000153) Xin Lang Zheng Quan·2025-10-23 11:32Core Viewpoint - The company has adjusted the repurchase price of the restricted stock incentive plan from 2.77 CNY/share to 2.67 CNY/share due to the implementation of the 2024 profit distribution plan, which includes a cash dividend of 1 CNY for every 10 shares [1][3][4]. Group 1: Background of the Incentive Plan - The restricted stock incentive plan was approved in August 2022, granting 19.97 million shares to 223 participants at a price of 4.13 CNY/share [2]. - The plan has undergone multiple approvals and implementations, with the board reviewing related matters periodically [2]. Group 2: Details of the Price Adjustment - The adjustment is based on the formula that accounts for cash dividends affecting stock prices, specifically reducing the repurchase price by the dividend amount of 0.1 CNY/share [3]. - The new repurchase price is calculated as follows: 2.77 CNY - 0.1 CNY = 2.67 CNY/share [3]. Group 3: Impact on the Company and Compliance - The company stated that the price adjustment will not materially affect its financial status or operational results [4]. - The adjustment has followed necessary internal approval processes, with legal opinions confirming compliance with relevant laws and regulations [4]. Group 4: Future Considerations - Following the price adjustment, the company will handle any future repurchase and cancellation of restricted stocks at the new price [5]. - Market analysts suggest that this adjustment is a standard practice to maintain the fairness and effectiveness of the incentive plan, potentially enhancing the motivation of the core team [5].